Metastatic potential of an aneurysmal bone cyst

Addy C. M. van de Luijtgaarden · Rene P. H. Veth · Piet J. Slootweg · Pauline M. Wijers-Koster · Leo J. Schultze Kool · Judith V. M. G. Bovee · Winette T. A. van der Graaf

Received: 29 July 2009 / Revised: 14 September 2009 / Accepted: 3 October 2009 / Published online: 17 October 2009
© The Author(s) 2009. This article is published with open access at Springerlink.com

Abstract Aneurysmal bone cysts (ABCs) are benign bone tumors consisting of blood-filled cavities lined by connective tissue septa. Recently, the hypothesis that ABCs are lesions reactive to local hemodynamics has been challenged after the discovery of specific recurrent chromosomal abnormalities. Multiple cases of malignant transformation of ABC into (osteosarcoma) have been described, as well as a number of cases of telangiectatic osteosarcoma which had been misdiagnosed as ABC. We herewith document a case of a pelvic ABC metastatic to the lung, liver, and kidneys. Diagnosis was confirmed by the presence of a break in the USP6 gene, which is pathognomonic for ABC, in a pulmonary metastasis of our patient. Sarcomatous transformation as an explanation for this behavior was ruled out by demonstrating diploid DNA content in both the pulmonary lesion and the primary tumor.

Keywords Bone cysts · Aneurysmal · Neoplasm metastasis · Image cytometry

Introduction

Primary aneurysmal bone cysts (ABC) account for 1–2% of all primary bone tumors and are usually present in the first two decades of life [1]. They are composed of blood-filled spaces separated by connective tissue septa that contain fibroblasts, osteoclast-type giant cells, and reactive woven bone [2]. The pathogenesis of primary ABC is still incompletely understood. In the past, ABCs were considered reactive lesions caused by altered local hemodynamics. More recently, it was shown that primary ABCs contain recurrent chromosomal abnormalities [3–13]. This suggests that primary ABCs are true neoplasms [1]. The differential diagnosis of primary ABC includes other giant cell-containing tumors of the bone, particularly giant cell tumor (GCT) [14]. ABC-like areas can also be seen in association with other tumors such as chondroblastoma (secondary ABC). Furthermore, cases of sarcomatous transformation of ABCs, often occurring after exposure to ionizing radiation, and of misdiagnosed telangiectatic osteosarcoma have been recognized. However, even without sarcomatous transformation, ABC may metastasize as is described in this report.

Clinical history

A 48-year-old woman was referred to our hospital for treatment of a giant ABC of the left ilium, measuring 27.6×22.4×15.9 cm (Fig. 1). Her medical history comprised of a hysterectomy for uterine cervical carcinoma in 1995, strumectomy for adenomatous thyroid hyperplasia in 1998,
and type II diabetes mellitus since 2004. For the ABC, she had been treated elsewhere with embolization (coiling and alcoholic zein injection; Ethibloc, Ethicon, Johnson & Johnson, New Brunswick, NJ, USA) and repeated surgery, all over a 1-year period. Wide local excision had not been achieved due to massive hemorrhage during surgical interventions. In our hospital, preoperative embolization and percutaneous intralesional alcohol injection were performed and staged resection of the alcohol-treated areas combined with cryosurgery was attempted. Furthermore, off-label systemic treatment with the monoclonal antivascular endothelial growth factor (VEGF) antibody bevacizumab (Avastin; Roche, Basel, Switzerland; Genentech, South San Francisco, California, USA) 10 mg/kg administered intravenously every other week was applied to reduce bleeding tendency. The latter was based on the reports by Kumta et al. and Shinde et al. showing VEGF positivity in 100% and 50% of primary ABCs, respectively [15, 16]. In our patient, plasma and cyst fluid VEGF levels were determined by enzyme-linked immunosorbent assay and found to be elevated (1.12 and 16.5 ng/ml, respectively; in-house control series of 23 healthy women: plasma average=0.166 ng/ml, range=0.028–0.966 ng/ml).

This strategy facilitated near-complete resection of the ABC by limiting intraoperative blood loss. However, clinical heart failure developed in our patient, prompting the discontinuation of bevacizumab. This was followed by a rapid regrowth of the pelvic lesion. After a total of seven surgical sessions, the patient’s condition no longer allowed surgical interventions and it was decided to apply radiotherapy at a total dose of 39 Gy. Unexpectedly, at this time, radiographical treatment evaluation showed previously undiscovered lesions in both lungs and in the left kidney. Widespread metastatic behavior of this until then judged benign bone neoplasm was suspected, while differential diagnosis included secondary ABC in a yet unidentified primary bone malignancy, malignant transformation of ABC, misdiagnosed GCT, or telangiectatic osteosarcoma. The patient’s condition no longer allowed any treatment and she died 2 years after ABC was first diagnosed. At autopsy, metastases were found in both lungs, both kidneys, and the liver.

**Materials and methods**

**Pathology**

Formalin-fixed paraffin-embedded specimens were available from all resections of the primary tumor. Sections from all samples were stained by the hematoxylin and
eosin method and re-examined for evidence of malignancy by multiple expert pathologists (PS, JB, and independent multidisciplinary revision by the Netherlands Committee on Bone Tumors).

**Image cytometry**

Three samples (two were obtained from the primary tumor at referral to our hospital and during the last resection, respectively, and the third was a pulmonary metastasis obtained during autopsy) were selected for DNA quantification by image cytometry. At least two 50-µm-thick sections were obtained of each sample followed by a 4-µm hematoxylin and eosin section to check for representativeness. An adaptation of the method described by Hedley [17] was used for cell nuclei extraction from the sections. The obtained suspensions were filtered with a Partec 50-µm CellTrics filter (Partec, Münster, Germany) and prepared into a monolayer by cytospin. Nuclei were stained with Feulgen's stain and periodic acid Schiff. The samples were evaluated using a cytometric image analysis system (QPATH, Leica Imaging Systems, Cambridge, UK) that consists of an automated microscope with a digital camera connected to a computer that runs DNA analysis software. Of each specimen, 5,000 nuclei were scanned and a minimum of 2,000 images of tumor cell nuclei were manually selected avoiding debris, necrotic or cut cells, and cell clusters. Lymphocytes were used as the standard internal controls. Histogram quality was evaluated by integrated optical density (IOD) values and its coefficient of variation (CV); $15 \leq \text{IOD} \leq 25$ and $\text{CV} \leq 5\%$ were considered acceptable. Criteria for ploidy classification were taken from the guidelines of the European Society for Analytical Cellular Pathology [18].

**Fluorescence in situ hybridization**

Fluorescence in situ hybridization (FISH) was performed on the lung metastasis using BAC probes flanking the \textit{USP6} gene, largely as described [19].

**Results**

Histological examination of material obtained from the primary tumor in the pelvis during the first surgical procedure showed a multicystic lesion with blood-filled spaces (Fig. 2a). The septa consisted of fibroblasts which showed no cytological features of malignancy such as nuclear atypia or an increased number of mitoses. Interspersed were woven bone fragments. No evidence of an underlying primary lesion causing secondary ABC, neither of evident malignant transformation of ABC, GCT, nor telangiectatic osteosarcoma was found. The morphology of the primary lesion was thus consistent with a primary ABC. The other excision specimens subsequently obtained from this pelvic tumor showed similar histology. The lung lesion resembled the solid parts of the pelvic location; no blood-filled cystic spaces were found here (Fig. 2b). Again, no cytological features of malignancy were found. The three samples (two obtained from the primary tumor and one pulmonary lesion) that were evaluated for DNA content were diploid. FISH performed on the pulmonary lesion showed a break in the \textit{USP6} gene in up to 43% of the nuclei; 24% of the nuclei showed segregation of the signal in addition to two normal (colocalization) chromosomes 17 (Fig. 3, left panel), 15% of the nuclei showed two normal chromosomes 17 and a single red signal (Fig. 3, middle panel), 4% showed one colocalization and one segregation of the signal (Fig. 3, right panel).

![Fig. 3](image.png)  
**Fig. 3** FISH images of the lung lesion removed at autopsy using BAC probes flanking the \textit{USP6} gene showing segregation of the signal and colocalization of two normal chromosomes 17 (left panel), two normal chromosomes 17 and a single red signal (middle panel), and one colocalization and one segregation of the signal (right panel)
Discussion

Since the discovery of recurrent chromosomal abnormalities, of which t(16;17)(q22;p13) is the most frequent [3–13], primary ABC is no longer considered a reactive lesion but rather a true benign neoplasm [1]. The t(16;17) translocation was later shown to relocate the promoter of CDH11, a gene that is strongly expressed in bone, in front of the USP6 gene (TRE2, TRE17) [8]. Over the past few years, a series of different translocations has been described in ABC [8, 13], all resulting in oncogenic activation of the USP6 gene on chromosome 17p13. Thus, the pathogenesis of most primary ABCs involves upregulation of USP6 transcription driven by other highly active promoters [20]. The mechanism by which USP6 upregulation causes ABC formation has not yet been elucidated. USP6 rearrangements were shown to be restricted to the spindle cells and were absent in the multinucleated giant cells, inflammatory cells, endothelial cells, and osteoblasts [8]. This suggests that the neoplastic spindle cells induce a vigorous, reactive host response mimicking young granulation tissue, explaining why for a long time the lesions were regarded reactive [8]. The majority of ABC patients are treated by local curettage combined with intraoperative adjuvant therapy (e.g., cryosurgery or phenol application) with local control rates as high as 70–90%. Almost all cases of recurrence can be treated by re-resection [1].

To our knowledge, there are no previous reports of metastatic behavior of primary ABC. Therefore, we considered the possibility of secondary ABC in a yet unidentified primary bone malignancy, malignant transformation of ABC, misdiagnosed GCT, or telangiectatic osteosarcoma. ABC-like areas can be seen in association with GCT, occasionally overgrowing the underlying primary tumor, and ABC can contain solid areas strongly resembling GCT [21]. In contrast with ABC, GCT may metastasize in 2–3% of cases, particularly to the lungs. The diploid DNA content we found cannot exclude GCT with metastatic potential [22, 23]. However, while chromosome 16 and 17 abnormalities have been found infrequently in GCT [24–26], the t(16;17)(q22;p13) translocation [8, 27] and USP6 upregulation [8] are absent in reported cases. We also tested three GCTs and could not detect a USP6 rearrangement (data not shown). Thus, it seems highly unlikely that our case represented metastasizing GCT of bone. Moreover, the USP6 rearrangement was demonstrated in the lung metastasis, indicating that, even if from the beginning it had been ABC secondary to and totally overgrowing an underlying primary bone lesion such as GCT, it is the ABC part that metastasized. Moreover, USP6 rearrangements have not been found in secondary ABC so far [19].

Telangiectatic osteosarcoma and ABC can be radiologically identical and histologically very difficult to disting-uish [28–30]. Nuclear atypia and an increased number of mitoses favor telangiectatic osteosarcoma. As an additional diagnostic tool, several reports have suggested the use of DNA cytometry to distinguish these entities. Whereas ABCs are known for diploid DNA content, telangiectatic osteosarcomas show complex karyotypes and numerous gains and losses [31–33]. Moreover, in ABC, CDH11-USP6 fusions as well as USP6 upregulation are pathognomonic, while they are absent in osteosarcoma [8, 9]. So, the diploid nature of the lesion in our case, both in primary as well as metastatic deposits, adequately rules out telangiectatic osteosarcoma as an alternative diagnosis.

In summary, in our patient, all histological samples obtained over a 2-year period were consistent with ABC while lacking cytological features of malignancy. Absence of malignant transformation was supported by DNA content analysis: three selected samples including a pulmonary metastasis all had diploid DNA content. Finally, we found a rearrangement of the USP6 gene by FISH in 43% of nuclei in the pulmonary lesion, which is within the highly variable range of positive cells (7–82%) reported for ABC [19]. We ruled out sarcomatous transformation or GCT as cause of the metastatic behavior and confirmed the diagnosis of ABC by our FISH data.

It can be hypothesized that the numerous surgical and interventional radiological manipulations that were necessary in our patient have facilitated the hematogenous spread of ABC cell clusters. Furthermore, though bevacizumab proved successful in reducing bleeding tendency, recent reports about antiangiogenic therapy-induced malignant progression of tumors to increased invasion and accelerated metastasis raise concern about a similar effect in our patient.

Acknowledgements We thank Dr. K. Szuhai for the help with the FISH analysis and the Netherlands Committee on Bone Tumors for their critical reappraisal of all histological samples obtained from this patient.

Conflict of interest statement The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Mendenhall WM, Zlotecki RA, Gibbs CP et al (2006) Aneurysmal bone cyst. Am J Clin Oncol 29(3):311–315
2. Rosenberg AE, Nielsen GP, Fletcher JA (2002) Aneurysmal bone cyst. In: Fletcher CDM, Unni KK, Mertens F (eds) World Health Organization classification of tumours: pathology and genetics of tumours of soft tissue and bone. International Agency for Research on Cancer, Lyon, pp 338–339
3. Althof PA, Ohmori K, Zhou M et al (2004) Cytogenetic and molecular cytogenetic findings in 43 aneurysmal bone cysts:
aberrations of 17p mapped to 17p13.2 by fluorescence in situ hybridization. Mod Pathol 17(5):518–525
4. Baruffi MR, Neto JB, Barbieri CH et al (2001) Aneurysmal bone cyst with chromosomal changes involving 7q and 16p. Cancer Genet Cytogenet 129(2):177–180
5. Dal CP, Kozakewich HP, Guummerova L et al (2000) Variant translocations involving 16q22 and 17p13 in solid variant and extraosseous forms of aneurysmal bone cyst. Genes Chromosomes Cancer 28(2):233–234
6. Ellison DA, Sawyer JR, Parham DM et al (2007) Soft-tissue aneurysmal bone cyst: report of a case with t(5;17)(q33;p13). Pediatr Dev Pathol 10(1):46–49
7. Kenney B, Richkind KE, Zambrano E (2007) Solid variant of aneurysmal bone cyst with a novel (X;9) translocation. Cancer Genet Cytogenet 178(2):155–159
8. Oliveira AM, Hsi BL, Weremowicz S et al (2004) USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst. Cancer Res 64(6):1920–1923
9. Panoutsakopoulos G, Pandis N, Kyriazoglou I et al (1999) Recurrent t(16;17)(q22;p13) in aneurysmal bone cysts. Genes Chromosomes Cancer 26(3):265–266
10. Sciorti R, Dorfman H, Brys P et al (2000) Cytogenetic–morphologic correlations in aneurysmal bone cyst, giant cell tumor of bone and combined lesions. A report from the CHAMP study group. Mod Pathol 13(11):1206–1210
11. Winnepenninckx V, biec-Rychter M, Jorissen M et al (2001) Aneurysmal bone cyst of the nose with 17p13 involvement. Virchows Arch 439(5):636–639
12. Wyatt-Ashmead J, Bao L, Eilert RE et al (2001) Primary aneurysmal bone cyst: 16q22 and/or 17p13 chromosome abnormalities. Pediatr Dev Pathol 4(4):418–419
13. Oliveira AM, Perez-Atayde AR, Dal CP et al (2005) Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes. Oncogene 24(21):3419–3426
14. Rosenberg AE, Nielsen GP (2001) Giant cell containing lesions of bone and their differential diagnosis. Curr Diagn Pathol 7(4):235–246
15. Kumta SM, Huang L, Cheng YY et al (2003) Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. Life Sci 73(11):1427–1436
16. Shinde A, Mehlman CT, Collins MH (2006) Aneurysmal bone cysts express vascular markers. Pediatr Dev Pathol 9(1):38–43
17. Hung JJ, Yang CP, Jaing TH (2003) Patterns of cancer distribution in a medical center among adolescents 14 to 17 years of age for the period 1995 to 2001. J Formos Med Assoc 102(9):631–636
18. Haroske G, Baak JP, Danielsen H et al (2001) Fourth updated ESACP consensus report on diagnostic DNA image cytometry. Anal Cell Pathol 23(2):89–95
19. Oliveira AM, Perez-Atayde AR, Inwards CY et al (2004) USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts. Am J Pathol 165(5):1773–1780
20. Oliveira AM, Chou MM, Perez-Atayde AR et al (2006) Aneurysmal bone cyst: a neoplasm driven by upregulation of the USP6 oncogene. J Clin Oncol 24(1):e1
21. Vergel De Dios AM, Bond JR, Shives TC et al (1992) Aneurysmal bone cyst. A clinicopathologic study of 238 cases. Cancer 69(12):2921–2931
22. Osaka S, Torigaya M, Taiga K et al (1997) Analysis of giant cell tumor of bone with pulmonary metastases. Clin Orthop Relat Res 335:253–261
23. Takamani I, Imamura T, Morota N et al (1994) Recurrent pulmonary metastases from benign giant cell tumors of the bone: report of two cases and analysis of nuclear DNA content by flow cytometry. Surg Today 24(5):476–480
24. Bridge JA, Neff JR, Mouron BJ (1992) Giant cell tumor of bone. Chromosomal analysis of 48 specimens and review of the literature. Cancer Genet Cytogenet 58(1):2–13
25. Molenaar WM, van den Berg E, Dolfin AC et al (1995) Cytogenetics of fine needle aspiration biopsies of sarcomas. Cancer Genet Cytogenet 84(1):27–31
26. Gorunova L, van Vult SF, Storlazzi CT et al (2009) Cytogenetic analysis of 101 giant cell tumors of bone: nonrandom patterns of telomeric associations and other structural aberrations. Genes Chromosomes Cancer 48(7):583–602
27. Mitelman F, Johansson B, Mertens F (eds) (2008) Mitelman database of chromosome aberrations in cancer. Ref type: Data file. Available at http://cgap.nci.nih.gov/Chromosomes/Mitelman
28. Gomes H, Menanteau B, Gaillard D et al (1986) Telangiectatic osteosarcoma. Pediatr Radiol 16(2):140–143
29. Vanel D, Tcheng S, Contesso G et al (1987) The radiological appearances of telangiectatic osteosarcoma. A study of 14 cases. Skeletal Radiol 16(3):196–200
30. Vigliani F, Campailla E (1987) Mimickry in osteogenic sarcoma. Clinical considerations and report of 2 cases. Ital J Orthop Traumatol 13(4):425–436
31. el-Naggar AK, Hurr K, Tu ZN et al (1995) DNA and RNA content analysis by flow cytometry in the pathobiologic assessment of bone tumors. Cytometry 19(3):256–262
32. Werner M, Heintz A, Delling G (1996) DNA cytometry of solitary and aneurysmal bone cysts and low malignancy and high malignancy central osteosarcomas. Current significance within the scope of morphologic diagnosis of intraosseous cystic and osteoblastic lesions. Pathol 17(1):44–49
33. Bauer HC, Kreiebergs A, Silfversward C et al (1988) DNA analysis in the differential diagnosis of osteosarcoma. Cancer 61(12):2532–2540